# Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

## A-205804

Cat. No.: HY-100226

A-205804 is an orally bioavailable, potent and selective lead inhibitor of **E-selectin** and **ICAM-1** expression, with an $IC_{50}$ of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.



**Purity:** 98.12%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 10 mg, 50 mg

## A-286982

Cat. No.: HY-107587

A-286982 is a potent and allosteric **LFA-1/ICAM-1 interaction** inhibitor with $IC_{50}$s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding and LFA-1-mediated cellular adhesion assay, respectively.



**Purity:** 99.69%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg

## Alicaforsen

(ISIS-2302)

Cat. No.: HY-145728

Alicaforsen is a 20-base antisense oligonucleotide inhibiting **ICAM-1** production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation.


**Purity:** >98%
**Clinical Data:** Phase 3
**Size:** 1 mg, 5 mg

## Arg-Gly-Asp-Ser

(RGDS peptide; Fibronectin tetrapeptide)

Cat. No.: HY-12290

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits **integrin receptor** function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.



**Purity:** 99.76%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

## Arg-Gly-Asp-Ser (TFA)

(RGDS peptide (TFA); Fibronectin tetrapeptide (TFA))

Cat. No.: HY-12290A

Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits **integrin receptor** function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.



**Purity:** >98%
**Clinical Data:**
**Size:** 1 mg, 5 mg

## ATN-161

Cat. No.: HY-13535

ATN-161 is a novel **integrin α5β1** antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.



**Purity:** >98%
**Clinical Data:** Phase 2
**Size:** 1 mg, 5 mg

## ATN-161 trifluoroacetate salt

(ATN-161 TFA salt)

Cat. No.: HY-13535A

ATN-161 trifluoroacetate salt is a novel **integrin α5β1** antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.



**Purity:** ≥95.0%
**Clinical Data:** Phase 2
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

## Bexotegrast

Cat. No.: HY-137561

Bexotegrast is a potent inhibitor of **αvβ6 integrin**. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) (extracted from patent WO2020210404A1, compound 5).



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## BI-1950

Cat. No.: HY-124040

BI-1950 is a highly potent **lymphocyte function associated antigen-1 (LFA-1)** inhibitor. LFA-1 is an essential component in normal immune system function and a target for drug discovery.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## BIO-1211

Cat. No.: HY-14126

BIO-1211 is a highly selective and orally active **α4β1 (VLA-4)** inhibitor, with $IC_{50}$ values of 4 nM and 2 μM for α4β1 and α4β7, respectively.



**Purity:** 99.64%
**Clinical Data:** No Development Reported
**Size:** 1 mg


Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

## BIO5192

Cat. No.: HY-107589

BIO5192 is a selective and potent integrin **α4β1** (VLA-4) inhibitor ($K_d$<10 pM). BIO5192 selectively binds to α4β1 ($IC_{50}$=1.8 nM) over a range of other integrins.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg

## BIO5192 hydrate

Cat. No.: HY-107589A

BIO5192 hydrate is a selective and potent integrin **α4β1 (VLA-4)** inhibitor ($K_d$<10 pM). BIO5192 hydrate selectively binds to α4β1 ($IC_{50}$=1.8 nM) over a range of other integrins.



**Purity:** ≥98.0%
**Clinical Data:** No Development Reported
**Size:** 1 mg

## BIRT 377

Cat. No.: HY-110117

BIRT 377 is a potent amd orally bioavailable inhibitor of the interaction between intercellular adhesion molecule-1 (ICAM-1) and **lymphocyte function-associated antigen-1 (LFA-1)**, with a $K_i$ of 25.8 nM. BIRT 377 also inhibits the production of IL-2 in vivo.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## BMS-587101

Cat. No.: HY-120628

BMS-587101 is a potent and orally active antagonist of **leukocyte function associated antigen-1 (LFA-1)**. BMS-587101 has anti-inflammatory effects and can be used for rheumatoid arthritis research.



**Purity:** 98.67%
**Clinical Data:** Phase 2
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## BMS-688521

Cat. No.: HY-10596

BMS-688521 is a highly potent, orally active inhibitor of the **LFA-1/ICAM** interaction, with an $IC_{50}$ of 2.5 nM in the adhesion assay and an $IC_{50}$ of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model.



**Purity:** 98.72%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg

## BOP sodium

Cat. No.: HY-129453

BOP sodium is a potent and selective dual **α9β1/α4β1 integrin** inhibitor with $K_d$ values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## c(phg-isoDGR-(NMe)k)

Cat. No.: HY-111413

c(phg-isoDGR-(NMe)k) is a selective and potent **α5β1-integrin** ligand with an $IC_{50}$ of 2.9 nM.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

## c(phg-isoDGR-(NMe)k) TFA

Cat. No.: HY-111413A

c(phg-isoDGR-(NMe)k) TFA is a selective and potent **α5β1-integrin** ligand with an $IC_{50}$ of 2.9 nM.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

## Carotegrast

Cat. No.: HY-14857

Carotegrast is an orally available **α4 integrin receptor** inhibitor with anti-inflammatories activities.



**Purity:** 98.14%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Carotegrast methyl

(AJM300)

Cat. No.: HY-124290

Carotegrast methyl (AJM300) is an orally active and selective **α4 integrin** antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice. <br/>.



**Purity:** 99.72%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Cilengitide
(EMD 121974)

Cat. No.: HY-16141

Cilengitide (EMD 121974) is a potent and selective inhibitor of the **integrins $\alpha_v\beta_3$** and **$\alpha_v\beta_5$**. Cilengitide inhibits binding of isolated $\alpha_v\beta_3$ and $\alpha_v\beta_5$ to Vitronectin with an $IC_{50}$ value of 4 and 79 nM, respectively .



**Purity:** 99.32%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Cilengitide TFA
(EMD 121974 TFA)

Cat. No.: HY-16143

Cilengitide is a potent and selective **integrin** inhibitor for $\alpha_v\beta_3$ and $\alpha_v\beta_5$ receptor, with **$IC_{50}$** values of 4 nM and 79 nM, respectively.



**Purity:** 98.85%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

## Cucurbitacin B

Cat. No.: HY-N0416

Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids; could repress cancer cell progression.



**Purity:** 99.92%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

## CWHM-12

Cat. No.: HY-18644

CWHM-12 is a potent inhibitor of **αV integrins** with **$IC_{50}$**s of 0.2, 0.8, 1.5, and 1.8 nM for **αvβ8**, **αvβ3**, **αvβ6**, and **αvβ1**.



**Purity:** 99.65%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Cyclo(-RGDfK)

Cat. No.: HY-P0023

Cyclo(-RGDfK) is a potent and selective inhibitor of the **$\alpha_v\beta_3$** integrin, with an **$IC_{50}$** of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.



**Purity:** ≥98.0%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Cyclo(-RGDfK) TFA

Cat. No.: HY-P0023A

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the **$\alpha_v\beta_3$** integrin, with an **$IC_{50}$** of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.



**Purity:** 99.81%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

Cat. No.: HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of **integrin αvβ3**, with antitumor activity.



**Purity:** 99.40%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Cyclo(RADfK)

Cat. No.: HY-P0031

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.



**Purity:** 98.03%
**Clinical Data:** No Development Reported
**Size:** 1 mg

## Cyclo(RGDyK)

Cat. No.: HY-100563A

Cyclo(RGDyK) is a potent and selective **$\alpha_v\beta_3$ integrin** inhibitor with an **$IC_{50}$** of 20 nM.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Cyclo(RGDyK) trifluoroacetate

Cat. No.: HY-100563

Cyclo(RGDyK) trifluoroacetate is a potent and selective **$\alpha_v\beta_3$ integrin** inhibitor with an **$IC_{50}$** of 20 nM.



**Purity:** 99.92%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## E7820

**(ER68203-00)**

Cat. No.: HY-14571

E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a unique **angiogenesis** inhibitor suppressing an expression of **integrin alpha2** subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an $IC_{50}$ of 0.11 μg/ml.



**Purity:** 99.25%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

## Echistatin

Cat. No.: HY-P1189

Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of **platelet aggregation**. Echistatin is a potent inhibitor of **bone resorption** in culture.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg

## Echistatin TFA

Cat. No.: HY-P1189A

Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of **platelet aggregation**. Echistatin is a potent inhibitor of **bone resorption** in culture.



**Purity:** 95.13%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## EMD527040

Cat. No.: HY-101473

EMD527040 is a potent and highly selective **αvβ6** antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Eptifibatide

Cat. No.: HY-B0686

Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity.



**Purity:** 99.91%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

## Eptifibatide acetate

Cat. No.: HY-B0686A

Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity.



**Purity:** >98%
**Clinical Data:** Launched
**Size:** 1 mg, 5 mg

## Fibronectin

Cat. No.: HY-P3160

Fibronectin, a glycoprotein (~500 kDa) present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins.

Fibronectins

**Purity:** 97.40%
**Clinical Data:** No Development Reported
**Size:** 1 mg

## Firategrast

**(SB 683699)**

Cat. No.: HY-14951

Firategrast (SB 683699) is an orally active and specific **α4β1/α4β7 integrin** antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.



**Purity:** 99.88%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Fradafiban

**(BIBU-52)**

Cat. No.: HY-101720

Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a $K_d$ value of 148 nM.



**Purity:** >98%
**Clinical Data:** Phase 1
**Size:** 1 mg, 5 mg

## GLPG0187

Cat. No.: HY-100506

GLPG0187 is a broad spectrum **integrin** receptor antagonist with antitumor activity; inhibits $\alpha_V\beta_1$-integrin with an $IC_{50}$ of 1.3 nM.



**Purity:** 99.78%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

## Gly-Arg-Gly-Asp-Ser

Cat. No.: HY-P0295

Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated $IC_{50}$ of 5 and 6.5 μM.



Purity: 95.05%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 25 mg

## Gly-Arg-Gly-Asp-Ser TFA

Cat. No.: HY-P0295A

Gly-Arg-Gly-Asp-Ser (TFA) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to **integrin receptors** αvβ3 and αvβ5 with estimated $IC_{50}$ of 5 and 6.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## GRGDSP

Cat. No.: HY-P0290

GRGDSP, a synthetic linear RGD peptide, is an **integrin** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

## GRGDSP TFA

Cat. No.: HY-P0290A

GRGDSP (TFA) is an **integrin** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

## HSDVHK-NH2

Cat. No.: HY-P1187

HSDVHK-NH2 is an antagonist of the **integrin αvβ3-vitronectin** interaction, with an $IC_{50}$ of 1.74 pg/mL (2.414 pM).<br/>.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

## HSDVHK-NH2 TFA

Cat. No.: HY-P1187A

HSDVHK-NH2 TFA is an antagonist of the **integrin αvβ3-vitronectin** interaction, with an $IC_{50}$ of 1.74 pg/mL (2.414 pM).<br/>.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## ICAM-1-IN-1

Cat. No.: HY-U00003

ICAM-1-IN-1 is a potent and selective inhibitor of **E-selectin** and **ICAM-1** with $IC_{50}$ values of 7 and 5 nM, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## ILK-IN-2

(OSU-T315 analog)

Cat. No.: HY-18676B

ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 50 mg

## ILK-IN-3

Cat. No.: HY-115677

ILK-IN-3 is an **integrin linked kinase** inhibitor with antitumor activity.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Integrin Antagonists 27

Cat. No.: HY-18668

Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Integrin modulator 1

Cat. No.: HY-134130

Integrin modulator 1 is a potent and selective **α4β1 integrin** agonist, with an $IC_{50}$ of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an $EC_{50}$ of 12.9 nM.



**Purity:** 99.43%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Integrin-IN-2

Cat. No.: HY-130119

Integrin-IN-2 (compound 39) is an orally bioavailable pan **αv integrin** inhibitor. Integrin-IN-2 can increases the **αvβ6**, **αvβ3**, **αvβ5** and **αvβ8** binding affinities with **pIC$_{50}$** values of 7.8, 8.4, 8.4 and 7.4, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## iRGD peptide

(c(CRGDKGPDC))

Cat. No.: HY-P0122

iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to **av integrins**, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.




**Purity:** 99.03%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

## Irigenin

Cat. No.: HY-N2587

Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking **α9β1** and **α4β1** integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties.



**Purity:** 99.84%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 20 mg

## LDV

Cat. No.: HY-P2267

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells.



**Purity:** >98%
**Clinical Data:** Phase 4
**Size:** 1 mg, 5 mg

## Leukadherin-1

Cat. No.: HY-15701

Leukadherin-1, a specific agonist of the leukocyte surface integrin **CD11b/CD18**, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an $EC_{50}$ of 4 μM.



**Purity:** ≥98.0%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## Lifitegrast

(SAR 1118; SHP-606)

Cat. No.: HY-19344

Lifitegrast (SAR 1118) is an integrin lymphocyte function-associated antigen-1 (**LFA-1; αLβ2**) antagonist; inhibits Jurkat T cell attachment to **ICAM-1** with an $IC_{50}$ of 2.98 nM.



**Purity:** 99.58%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

## LXW7

Cat. No.: HY-P0178

LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an **integrin αvβ3** inhibitor. LXW7 has a high binding affinity to **αvβ3 integrin** with an $IC_{50}$ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## LXW7 TFA

Cat. No.: HY-P0178A

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an **integrin αvβ3** inhibitor. LXW7 has a high binding affinity to **αvβ3 integrin** with an $IC_{50}$ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.



**Purity:** 99.17%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

## MK-0429

(L-000845704)

Cat. No.: HY-15102

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide **pan-integrin** antagonist with $IC_{50}$ values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively.



**Purity:** 99.84%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Natalizumab

Cat. No.: HY-108831

Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-**integrin** and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Natalizumab

**Purity:** >98%
**Clinical Data:** Launched
**Size:** 10 mg, 25 mg

## OSU-T315

Cat. No.: HY-18676

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase **(ILK)** inhibitor with an $IC_{50}$ of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain).



**Purity:** 99.88%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Pyrintegrin

Cat. No.: HY-13306

Pyrintegrin is an **β1-integrin** agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated **integrin** signaling.



**Purity:** 97.04%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## R-BC154 acetate

Cat. No.: HY-136214

R-BC154 acetate is a selective fluorescent $\alpha_9\beta_1$ integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## RGD

Cat. No.: HY-P0278

RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to **integrins**.



**Purity:** >98%
**Clinical Data:** Phase 2
**Size:** 1 mg, 5 mg

## RGD peptide (GRGDNP)

Cat. No.: HY-P1740

RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## RGD peptide (GRGDNP) (TFA)

Cat. No.: HY-P1740A

RGD peptide (GRGDNP) (TFA) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation.



**Purity:** 99.25%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## RGD Trifluoroacetate

Cat. No.: HY-P0278A

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to **integrins**.



**Purity:** ≥98.0%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## RO0270608

Cat. No.: HY-138542

RO0270608, the active metabolite of R411, is a dual **alpha4beta1-alpha4beta7 (α4β1/α4β7)** integrin antagonist. Antiinflammatory activity.



**Purity:** 98.69%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## RWJ 50271

Cat. No.: HY-110086

RWJ 50271 is an selective and orally active inhibitor of **lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1)** interaction with an **$IC_{50}$** of 5.0 μM (HL60 cells). RWJ 50271 inhibits LFA-1/ICAM-1-mediated cell adhesion.



**Purity:** 99.51%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg

## SB-267268

Cat. No.: HY-19306

SB-267268 is a selective and nonpeptidic **alpha(v)beta3 (αvβ3)** and **alpha(v)beta5 (αvβ5)** integrins antagonist, with $K_i$s of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Sibrafiban

**(RO 48-3657)**

Cat. No.: HY-10309

Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 and a selective **glycoprotein IIb/IIIa receptor** antagonist. Sibrafiban inhibits platelet aggregation.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## SR121566A

Cat. No.: HY-U00235

SR121566A is a novel non-peptide **Glycoprotein IIb/IIIa** (**GP IIb-IIIa**) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with $IC_{50}$s of 46±7.5, 56±6 and 42±3 nM, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## TC-I 15

Cat. No.: HY-107588

TC-I 15 (TC-I-15) is an allosteric, collagen-binding integrin **α2β1** inhibitor with $IC_{50}$ values of 26.8 μM and 0.4 μM for GFOGER and GLOGEN, respectively. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## TC113

Cat. No.: HY-145314

TC113 is a c(RGDyK)-Based conjugate of Gemcitabine (GEM). TC113 could be internalized by A549 cells through integrin $\alpha_v\beta_3$. TC113 shows potent antiproliferative properties against WM266.4 and A549 cells.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## TCS 2314

Cat. No.: HY-12308

TCS 2314 (compound 3) is orally active and selective **very late antigen-4 (VLA-4, α4β1, CD49d/CD29)** antagonist with an $IC_{50}$ of 4.4 nM.



**Purity:** ≥99.0%
**Clinical Data:** No Development Reported
**Size:** 5 mg

## Tetrac (Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid)

Cat. No.: HY-W008859

Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a **thyrointegrin receptor** antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on **integrin αvβ3**.



**Purity:** ≥95.0%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 10 mg, 25 mg

## THI0019

Cat. No.: HY-117388

THI0019 is a potent **integrin α4β1 (VLA-4)** agonist with an $EC_{50}$ range of 1-2 μM. THI0019 induces stem/progenitor cells adhesion. THI0019 also regulates adhesion mediated by α4β7, α5β1 and αLβ2.



**Purity:** 98.31%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Tirofiban

**(L700462; MK383)**

Cat. No.: HY-17369B

Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.



**Purity:** 98.37%
**Clinical Data:** Launched
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

## Tirofiban hydrochloride monohydrate

Cat. No.: HY-17369

Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist IC50 value: Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.



**Purity:** 99.34%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Tirofiban-d9

(L700462-d9; MK383-d9) Cat. No.: HY-17369BS

Tirofiban-d9 is deuterium labeled Tirofiban.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## Tirofiban-d9 hydrochloride

Cat. No.: HY-17369AS

Tirofiban-d9 (L700462-d9) hydrochloride is the deuterium labeled Tirofiban. Tirofiban(L700462) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

## TR-14035

Cat. No.: HY-15770

TR-14035 is a orally active dual $\alpha_4\beta_7/\alpha_4\beta_1$ **integrin** antagonist, with $IC_{50}$ s of 7 nM and 87 nM for $\alpha_4\beta_7$ and $\alpha_4\beta_1$, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Valategrast

(R-411 free base) Cat. No.: HY-14190

Valategrast (R-411 free base) is a potent and orally active **integrin α4β1 (VLA-4)** and **α4β7** dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Valategrast hydrochloride

(R-411) Cat. No.: HY-14189

Valategrast hydrochloride (R-411) is a potent **integrin α4β1 (VLA-4)** and **α4β7** dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Vedolizumab

(Anti-Human lymphocyte α4β7 integrin, Humanized Antibody) Cat. No.: HY-P9911

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 **integrin** for the treatment of ulcerative colitis and Crohn's disease.

Vedolizumab

Purity: 99.64%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

## Vedolizumab (anti-α4β7-integrin)

Cat. No.: HY-P9911A

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 **integrin** for the treatment of ulcerative colitis and Crohn's disease.

Vedolizumab (anti-$\alpha_4\beta_7$-integrin)

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

## XVA143

Cat. No.: HY-139202

XVA143, an α/β I-like allosteric antagonist, inhibits **LFA-1** dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## Zauategrast

(CT7758) Cat. No.: HY-70073

Zauategrast (CT7758) is a potent and oral-effective **$\alpha_4$-integrin** inhibitor.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

## Zauategrast ethyl ester

(CDP323; UCB1184197) Cat. No.: HY-75385

Zauategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a **α4β1/α4β7** integrin antagonist used for the treatment of inflammatory and autoimmune disorders.



Purity: 99.06%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

## Zauategrast ethyl ester sulfate

**(CDP323 sulfate; UCB1184197 sulfate)**

Cat. No.: HY-75385A

Zauategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a **α4β1/α4β7** integrin antagonist used for the treatment of inflammatory and autoimmune disorders.



**Purity:** >98%
**Clinical Data:** Phase 2
**Size:** 1 mg, 5 mg

## α2β1 Integrin Ligand Peptide

Cat. No.: HY-P1868

α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

## α2β1 Integrin Ligand Peptide TFA

Cat. No.: HY-P1868A

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.



**Purity:** 99.33%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

## α5β1 integrin agonist-1

Cat. No.: HY-139702

α5β1 integrin agonist-1, acting as **α5β1 integrin** agonist, is able to selectively deliver 5-FU into tumor cells, successfully leading to cancer cell death.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## αvβ1 integrin-IN-1

Cat. No.: HY-100445

αvβ1 integrin-IN-1 (Compound C8) is a potent and selective **αvβ1 integrin** inhibitor with an $IC_{50}$ of 0.63 nM. Antifibrotic effects.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

## αvβ1 integrin-IN-1 TFA

Cat. No.: HY-100445A

αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective **αvβ1 integrin** inhibitor with an $IC_{50}$ of 0.63 nM. Antifibrotic effects.



**Purity:** 98.30%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## αvβ5 integrin-IN-1

Cat. No.: HY-145363

αvβ5 integrin-IN-1 is a first potent and selective **αvβ5** integrin inhibitor ($pIC_{50}$ = 8.2) .



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg